Recently, ambient electrochemical N2 fixation has gained great attention. However, the commercial Pt‐based electrocatalyst hardly shows its potential in this field. Herein, it is found that the ...isolated Pt sites anchored on WO3 nanoplates exhibit the optimum electrochemical NH3 yield rate (342.4 µg h−1 mg−1Pt) and Faradaic efficiency (31.1%) in 0.1 m K2SO4 at −0.2 V versus RHE, which are about 11 and 15 times higher than their nanoparticle counterparts, respectively. The mechanistic analysis indicates that N2 conversion to NH3 follows an alternating hydrogenation pathway, and positively charged isolated Pt sites with special Pt−3O structure can favorably chemisorb and activate the N2. Furthermore, the hydrogen evolution reaction can be greatly suppressed on isolated Pt sites decorated WO3 nanoplates, which guarantees the efficient going‐on of nitrogen reduction reaction.
Isolated Pt atoms anchored on WO3 nanoplates exhibit highly active for ambient ammonia electrosynthesis, which is ascribed to facilitated chemisorption and activation of nitrogen and effective suppression for hydrogen evolution reaction (HER), immensely enhancing NH3 yield rate and Faradic efficiency. This groundbreaking research presents Pt‐based nanocatalysts for electroreduction of nitrogen and provides an idea for the HER depression.
The consensus problem for multi-agent systems with input and communication delays is studied based on the frequency-domain analysis. Two decentralized consensus conditions are obtained, one of which ...is given for the systems based on undirected graphs with diverse input delays and the other is for the systems based on directed graphs with diverse communication delays and input delays. For the systems with both communication delays and input delays, the consensus condition is dependent on input delays but independent of communication delays.
Water splitting for the production of hydrogen and oxygen is an appealing solution to advance many sustainable and renewable energy conversion and storage systems, while the key fact depends on the ...innovative exploration regarding the design of efficient electrocatalysts. Reported herein is the growth of CoP mesoporous nanorod arrays on conductive Ni foam through an electrodeposition strategy. The resulting material of well‐defined mesoporosity and a high specific surface area (148 m2 g−1) can be directly employed as a bifunctional and flexible working electrode for both hydrogen and oxygen evolution reactions, showing superior activities as compared with noble metal benchmarks and state‐of‐the‐art transition‐metal‐based catalysts. This is intimately related to the unique nanorod array electrode configuration, leading to excellent electric interconnection and improved mass transport. A further step is taken toward an alkaline electrolyzer that can achieve a current density of 10 mA cm−2 at a voltage around 1.62 V over a long‐term operation, better than the combination of Pt and IrO2. This development is suggested to be readily extended to obtain other electrocatalysis systems for scale‐up water‐splitting technology.
Flexible, bifunctional electrodes with self‐supported CoP mesoporous nanorod arrays are fabricated through an electrodeposition strategy. The electrodes possess well‐structured mesoporosity and a high specific surface area, exhibiting high activities toward both electrochemical hydrogen and oxygen evolution reactions. In a further step, an alkaline electrolyzer with a current density of 10 mA cm−2 at 1.62 V in a long‐term operation is realized.
Failure mode and effect analysis (FMEA) is a prospective reliability analysis technique used in a wide range of industries for enhancing the safety and reliability of systems, products, processes, ...and services. However, the conventional FMEA method has been criticized for inherent drawbacks that limit effectiveness and applications. In this paper, a novel integrated FMEA model based on cloud model theory and hierarchical technique for order of preference by similarity to ideal solution (TOPSIS) method is developed to assess and rank the risk of failure modes. First, individual linguistic assessments of failure modes are converted into normal clouds. Then, FMEA team members' weights are calculated based on the subjective weighting information. Finally, the risk priority of failure modes is determined by using the cloud hierarchical TOPSIS. The newly proposed FMEA method combines the advantages of the cloud model in coping with fuzziness and randomness of linguistic assessments and the merits of hierarchical TOPSIS in solving complex decision making problems. Two empirical examples to illustrate the feasibility and effectiveness of the proposed FMEA are presented together with a comparison to existing methods.
Abstract
Light projection displays play an increasingly important role in our modern life. Core projection systems including liquid crystal displays and digital micromirror devices can impose spatial ...light modulation and actively shape light waves. Recently, the advent of metasurfaces has revolutionized design concepts in nanophotonics, enabling a new family of optical elements with exceptional degrees of freedom. Here, we demonstrate a light projection display technology based on optical metasurfaces, called digital metasurface device (DMSD). Each metasurface pixel in a DMSD is electrically reconfigurable with well-controlled programmability and addressability. The DMSD can not only continuously modulate the intensity of light with high contrast, but also shape the wavefront of light generated by each metasurface pixel and dynamically switch between arbitrary holographic patterns. Our approach will pave an avenue towards the development of customized light projection devices. It will also drive the field of dynamic optical metasurfaces with fresh momentum and inspiring concepts.
T-cell receptor （TCR）-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCR- engineered T cells began more than ...two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCR- engineered T cells to target New York esophageal squamous cell carcinoma （NY-ESO-1）. These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment.
3-Hydroxypropionic acid (3HP), an important three carbon (C3) chemical, is designated as one of the top platform chemicals with an urgent need for improved industrial production. Halomonas ...bluephagenesis shows the potential as a chassis for competitive bioproduction of various chemicals due to its ability to grow under an open, unsterile and continuous process. Here, we report the strategy for producing 3HP and its copolymer poly(3-hydroxybutyrate-co-3-hydroxypropionate) (P3HB3HP) by the development of H. bluephagenesis. The transcriptome analysis reveals its 3HP degradation and synthesis pathways involving endogenous synthetic enzymes from 1,3-propanediol. Combing the optimized expression of aldehyde dehydrogenase (AldD
), an engineered H. bluephagenesis strain of whose 3HP degradation pathway is deleted and that overexpresses alcohol dehydrogenases (AdhP) on its genome under a balanced redox state, is constructed with an enhanced 1.3-propanediol-dependent 3HP biosynthetic pathway to produce 154 g L
of 3HP with a yield and productivity of 0.93 g g
1,3-propanediol and 2.4 g L
h
, respectively. Moreover, the strain could also accumulate 60% poly(3-hydroxybutyrate-co-32-45% 3-hydroxypropionate) in the dry cell mass, demonstrating to be a suitable chassis for hyperproduction of 3HP and P3HB3HP.
The U-shaped network is one of the end-to-end convolutional neural networks (CNNs). In electron microscope segmentation of ISBI challenge 2012, the concise architecture and outstanding performance of ...the U-shaped network are impressive. Then, a variety of segmentation models based on this architecture have been proposed for medical image segmentations. We present a comprehensive literature review of U-shaped networks applied to medical image segmentation tasks, focusing on the architectures, extended mechanisms and application areas in these studies. The aim of this survey is twofold. First, we report the different extended U-shaped networks, discuss main state-of-the-art extended mechanisms, including residual mechanism, dense mechanism, dilated mechanism, attention mechanism, multi-module mechanism, and ensemble mechanism, analyze their pros and cons. Second, this survey provides the overview of studies in main application areas of U-shaped networks, including brain tumor, stroke, white matter hyperintensities (WMHs), eye, cardiac, liver, musculoskeletal, skin cancer, and neuronal pathology. Finally, we summarize the current U-shaped networks, point out the open challenges and directions for future research.
Complex interactions between the immune system and tumor cells exist throughout the initiation and development of cancer. Although the immune system eliminates malignantly transformed cells in the ...early stage, surviving tumor cells evade host immune defense through various methods and even reprogram the anti-tumor immune response to a pro-tumor phenotype to obtain unlimited growth and metastasis. The high proliferation rate of tumor cells increases the demand for local nutrients and oxygen. Poorly organized vessels can barely satisfy this requirement, which results in an acidic, hypoxic, and glucose-deficient tumor microenvironment. As a result, lipids in the tumor microenvironment are activated and utilized as a primary source of energy and critical regulators in both tumor cells and related immune cells. However, the exact role of lipid metabolism reprogramming in tumor immune response remains unclear. A comprehensive understanding of lipid metabolism dysfunction in the tumor microenvironment and its dual effects on the immune response is critical for mapping the detailed landscape of tumor immunology and developing specific treatments for cancer patients. In this review, we have focused on the dysregulation of lipid metabolism in the tumor microenvironment and have discussed its contradictory roles in the tumor immune response. In addition, we have summarized the current therapeutic strategies targeting lipid metabolism in tumor immunotherapy. This review provides a comprehensive summary of lipid metabolism in the tumor immune response.
ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus ...vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (
) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.
From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and
-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was DFS (intention-to-treat ITT population). Secondary end points included OS, 3-, 5-year (y) DFS rates, and 5-year OS rate. Post hoc analysis was conducted for subsequent therapy data.
Median follow-up was 80.0 months. Median OS (ITT) was 75.5 and 62.8 months with gefitinib and VP, respectively (hazard ratio HR, 0.92; 95% CI, 0.62 to 1.36;
= .674); respective 5-year OS rates were 53.2% and 51.2% (
= .784). Subsequent therapy was administered upon progression in 68.4% and 73.6% of patients receiving gefitinib and VP, respectively. Subsequent targeted therapy contributed most to OS (HR, 0.23; 95% CI, 0.14 to 0.38) compared with no subsequent therapy. Updated 3y DFS rates were 39.6% and 32. 5% with gefitinib and VP (
= .316) and 5y DFS rates were 22. 6% and 23.2% (
= .928), respectively.
Adjuvant therapy with gefitinib in patients with early-stage NSCLC and
mutation demonstrated improved DFS over standard of care chemotherapy. Although this DFS advantage did not translate to a significant OS difference, OS with adjuvant gefitinib was one of the longest observed in this patient group compared with historic data.
PDF
